Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Tislelizumab, Chemotherapy, and Node-Sparing Radiotherapy for Locally Advanced Esophageal Cancer
NCT06965829Phase 2Not yet recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Jul 2025
- Primary completion
- Jul 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Shanghai Chest Hospital. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06965829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06965829.